Physician

Charles Thomas Humphries, MD

According to 2025 Medicare claims, Charles Humphries, MD (NPI: 1326154824) practices allergy/immunology in the Charlotte-Concord-Gastonia, NC-SC market, with the plurality of this provider's patient population coming from Mecklenburg, NC. This provider's primary affiliated billing organization is ASTHMA & ALLERGY SPECIALISTS, P.A. (NPI: 1013093038; TIN: 56-1913043) and primary practice location at 28277-8745.

Humphries' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 217 traditional Medicare patients, billed 7,923 HCPCS/CPT codes, and received $75,871 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,238 prescription claims across 195 beneficiaries totaling $267,665 in drug costs, led by Xolair (Omalizumab). DME data shows 65 claims. Open Payments data shows 24 records totaling $686. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $60,456 to $75,871. Similarly, Part D prescription costs have moved sharply higher in recent years, from $93,620 to $267,665. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $459 and ending at $808.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	162	6,367	$60,456
2016	176	5,882	$53,903
2017	186	6,313	$59,709
2018	217	6,936	$61,828
2019	221	6,658	$66,933
2020	174	5,257	$51,460
2021	246	9,292	$100,569
2022	253	8,766	$94,492
2023	223	8,535	$90,890
2024	217	7,923	$75,871

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	137	961	$93,620
2016	128	882	$103,216
2017	127	933	$109,013
2018	141	938	$114,832
2019	160	1,160	$199,299
2020	135	781	$145,369
2021	150	677	$139,596
2022	153	842	$170,829
2023	177	1,071	$302,527
2024	195	1,238	$267,665

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	55	$1,092
2016	N/R	47	$3,509
2017	N/R	42	$2,088
2018	N/R	22	$509
2019	N/R	93	$2,209
2020	N/R	57	$416
2021	N/R	14	$370
2022	N/R	55	$753
2023	N/R	36	$675
2024	12	65	$851

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	99	124	$77
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	109	118	$50
94010	Test to measure expiratory airflow and volume	49	55	$15
95165	Professional service for preparation and provision of 1 or more antigens	125	3,842	$9
95117	Professional service for multiple injections of allergen	119	1,745	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xolair	Omalizumab	39	1,092	$121,325
Breo Ellipta	Fluticasone/Vilanterol	54	2,340	$30,535
Advair Diskus	Fluticasone Propion/Salmeterol	37	1,290	$9,626
Arnuity Ellipta	Fluticasone Furoate	38	1,410	$9,453
Symbicort	Budesonide/Formoterol Fumarate	28	1,086	$8,426

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	12	26	$647
E0570	Nebulizer, with compressor	Y	N/R	23	$110
J7613	Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg	N	N/R	16	$95

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	24	$686	GENZYME CORPORATION
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Charles Thomas Humphries, MD?

Tedicare shows public-source Medicare data for Charles Thomas Humphries, MD (NPI 1326154824), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Charles Thomas Humphries, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Charles Thomas Humphries, MD?

Charles Thomas Humphries, MD is linked to ASTHMA & ALLERGY SPECIALISTS, P.A. (billing NPI 1013093038) in the available physician profile data.

Does Charles Thomas Humphries, MD have Open Payments data?

Charles Thomas Humphries, MD has 24 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.